Bills in Congress could directly lead to lower patient out-of-pocket costs for items like insulin and may indirectly impact expenses by curbing possible patent abuses.

Bills in Congress could directly lead to lower patient out-of-pocket costs for items like insulin and may indirectly impact expenses by curbing possible patent abuses.

The INSULIN Act would cap insulin costs for privately insured patients as Congress considers broader measures targeting drug patent practices and competition.